Equities research analysts at Barclays Capital (NYSE: BCS) upped their price target on shares of Incyte (NASDAQ: INCY) from $15.00 to $19.00 in a research note issued to investors on Friday. The firm currently has an “equal weight” rating on the stock.
INCY has been the subject of a number of other recent research reports. Analysts at UBS AG (NYSE: UBS) raised their price target on shares of Incyte from $22.00 to $26.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at ThinkEquity initiated coverage on shares of Incyte in a research note to investors on Friday, March 30th. They set a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of Incyte from an “underperform” rating to a “neutral” rating in a research note to investors on Monday, March 26th. They now have a $21.00 price target on the stock.
Incyte opened at 22.94 on Friday. Incyte has a 1-year low of $11.76 and a 1-year high of $23.01. The company’s market cap is $2.921 billion.
The company last announced its quarterly results on Thursday, April 26th. It reported ($0.36) earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.48) EPS by $0.12. The company’s quarterly revenue was up 13.1% on a year-over-year basis. Analysts expect that Incyte will post $-0.23 EPS next quarter.
Incyte Corporation (Incyte) is a drug discovery and development company, focused on developing small molecule drugs to treat serious unmet medical needs.